PYFA Strengthens Its Position in the Asia Pacific Market through a Strategic Partnership with Genewel.

Jakarta, August 29, 2025 – PT Pyridam Farma Tbk (PYFA) has announced a strategic move to strengthen its market penetration in the Asia Pacific region by forming an exclusive partnership with Genewel Co., Ltd., a leading South Korean company known for developing medical biomaterials, anti-adhesion agents, and advanced wound care technology.

Under this collaboration agreement, PYFA has obtained exclusive distribution rights for Genewel’s flagship products, including Medifoam, Welpass, and Guardix-SG, in Indonesia and other Southeast Asian countries. The exclusive rights give PYFA full authority over managing product registration, import, marketing, sales, and the sub-distributor network in the designated regions.

Demand for wound care solutions in Southeast Asia is projected to show strong growth in the coming years. This trend is supported by an increasing number of surgical procedures in the region, which drives the need for anti-adhesion barriers. Through this partnership, PYFA is in a strong position to accelerate its market share in this segment while solidifying its brand as a provider of integrated, global-standard healthcare solutions.

Antes Eko Prasetio, Chief Commercial Officer of PYFA, stated that this partnership not only expands the company’s geographical reach but also enhances its capacity to deliver world-class healthcare innovations. “This collaboration adds a range of international-quality products to our portfolio and extends our market reach into strategic countries in Southeast Asia. We are optimistic that we can boost market penetration, build cross-country distribution synergies, and provide relevant healthcare solutions for communities in Southeast Asia, including Indonesia,” he said.

Genewel Co., Ltd. has a strong track record of innovation, collaborating with various prominent research institutions in Korea. One result of this collaboration is Welpass, a sustained-release kit developed to improve post-operative pain management and enhance patient comfort. Welpass is designed as a patient-centric therapeutic solution that can be administered with pain medication. This drug delivery platform represents a significant innovation combining wound care technology with a drug delivery platform. Genewel’s research portfolio includes wound therapies, postoperative anti-adhesion solutions, biomaterials for tissue regeneration, and sustained-release drug delivery systems (DDS). These areas encompass biomaterial-based medical devices that meet global healthcare needs.

Sang Deok Han, Chief Executive Officer of Genewel, expressed his appreciation for the collaboration. “PYFA is a strategic partner with strong vision, integrity, and international distribution capabilities. Together with PYFA, we are not only expanding the market for Genewel’s products but also contributing to raising the standard of healthcare in Southeast Asia. We believe this collaboration will open up mutually beneficial, long-term growth opportunities,” he said.

This strategic partnership offers various added values for PYFA. Access to Genewel’s internationally tested and certified product portfolio ensures global quality standards. Through this exclusive distribution agreement, PYFA can expand its geographical reach in Southeast Asia and strengthen its market position. The expansion of this product portfolio targets the hospital and clinic market segments, which have more stable margins.

About PYFA

PT Pyridam Farma Tbk (Stock Code: PYFA), known by the brand PYFA Group, is a public company in the pharmaceutical sector listed on the Indonesia Stock Exchange. PYFA’s business units include supplements and prescription drugs in various forms, such as tablets, capsules, creams, and injections. PYFA is the controlling shareholder of several subsidiaries, including PT Holi Pharma in Cimahi, West Java; PT Ethica Industri Farmasi, which has a manufacturing facility in Cikarang, West Java; and Probiotec Pty Ltd in Australia.

About Genewel

Genewel Co., Ltd. is a South Korean company focused on the development and production of wound care products, anti-adhesion barriers, and advanced drug delivery systems. Genewel’s products have gained international recognition and are widely used in many countries.

Media Relations

Leilanie Nadia Kusuma
Website: www.pyfa.co.id
Email: corcomm@pyfa.co.id